Ionis Pharmaceuticals (IONS) Price & Analysis

Compare

1,357 Followers

IONS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$23.95 - $52.34

Previous CloseN/A

Volume126.35K

Average Volume (3M)1.40M

Market Cap

$5.95B

Enterprise Value$4.72B

Total Cash (Recent Filing)$2.15B

Total Debt (Recent Filing)$1.41B

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Jul 31, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding159,159,100

10 Day Avg. Volume1,716,449

30 Day Avg. Volume1,399,263

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)9.35

Price to Sales (P/S)0.00

P/FCF Ratio-18.19

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue1.55

Enterprise Value/Gross Profit6.72

Enterprise Value/Ebitda-3.82

Forecast

1Y Price Target

$56.06

Price Target Upside49.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering20

Ionis Pharmaceuticals News

See All IONS News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe trial hit the primary endpoint with statistically significant triglyceride reductions, indicating promising results for the treatment.

Safety ProfileA favorable safety and tolerability profile was noted, with injection site reactions being the most common but mostly mild in severity.

Bears Say

Market ImpactESSENCE is an incremental positive for Ionis, but it is not expected to be stock-moving as olezarsen’s mechanism of action was de-risked through prior studies.

Trial LimitationsThe readthrough to pivotal CORE/CORE2 studies is limited due to differences in patient characteristics compared to the ESSENCE study.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.80% Insiders

43.47% Mutual Funds

0.10% Other Institutional Investors

40.53% Public Companies and Individual Investors

Detailed Ownership Overview >

IONS FAQ

What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?

Ionis Pharmaceuticals Inc. lowest stock price was $23.95 and its highest was $52.34 in the past 12 months.

What is Ionis Pharmaceuticals Inc.’s market cap?

Ionis Pharmaceuticals Inc.’s market cap is $5.95B.

When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?

Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Jul 31, 2025 which is in 38 days.

How were Ionis Pharmaceuticals Inc.’s earnings last quarter?

Ionis Pharmaceuticals Inc. released its earnings results on Apr 30, 2025. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$1.098 by $0.168.

Is Ionis Pharmaceuticals Inc. overvalued?

According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ionis Pharmaceuticals Inc. pay dividends?

Ionis Pharmaceuticals Inc. does not currently pay dividends.

What is Ionis Pharmaceuticals Inc.’s EPS estimate?

Ionis Pharmaceuticals Inc.’s EPS estimate is -0.26.

How many shares outstanding does Ionis Pharmaceuticals Inc. have?

Ionis Pharmaceuticals Inc. has 159,159,100 shares outstanding.

What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?

Ionis Pharmaceuticals Inc. reported an EPS of -$0.93 in its last earnings report, beating expectations of -$1.098. Following the earnings report the stock price went up 3.019%.

Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in IONS

Ionis Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-118.53%

Trailing 12-Months

Asset Growth

1.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals (IONS) is a biotechnology company headquartered in Carlsbad, California. It specializes in discovering and developing RNA-targeted therapeutics, primarily focusing on antisense oligonucleotide technology. Ionis is recognized for its innovative approach to treating a wide range of diseases, including neurological disorders, cardiovascular diseases, and cancer. The company develops drugs both independently and through strategic collaborations with leading pharmaceutical companies.

IONS Company Deck

IONS Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Ionis demonstrated strong financial performance and successful product launches despite external market uncertainties. The company increased its financial guidance and highlighted significant growth potential through upcoming product launches. However, challenges remain in patient identification and potential market disruptions.Read More>

IONS Revenue Breakdown

60.82% R&D

39.18% Commercial

IONS Stock 12 Month Forecast

Average Price Target

$56.06

▲(49.85%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","79":"$79","39.25":"$39.3","52.5":"$52.5","65.75":"$65.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,39.25,52.5,65.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.11,37.48615384615385,40.862307692307695,44.238461538461536,47.614615384615384,50.99076923076923,54.36692307692307,57.74307692307692,61.11923076923077,64.49538461538461,67.87153846153846,71.2476923076923,74.62384615384616,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.11,35.79846153846154,37.48692307692308,39.175384615384615,40.863846153846154,42.55230769230769,44.24076923076923,45.92923076923077,47.61769230769231,49.30615384615385,50.994615384615386,52.683076923076925,54.371538461538464,{"y":56.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.11,34.40923076923077,34.708461538461535,35.00769230769231,35.30692307692308,35.606153846153845,35.90538461538461,36.20461538461539,36.503846153846155,36.80307692307692,37.10230769230769,37.401538461538465,37.70076923076923,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.57,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >